Healthy Clinical Trial
— OMEGOZOfficial title:
Efficacy of Fish Oil or Olive Oil Supplementation on the Health Effects of Ozone Exposure in Healthy Young Subjects
Verified date | January 2021 |
Source | University of North Carolina, Chapel Hill |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Purpose: A growing body of epidemiological data suggests an increased risk of cardiovascular events associated with air pollution. One of the common air pollutants, ozone, has been shown to induce oxidative stress and inflammation in the cardiovascular and respiratory systems. This proposed study is to examine the efficacy of fish oil and olive oil in modulating cardiovascular and pulmonary functions after ozone exposure. The objective is to understand the mechanistic basis for the health effects of ozone relative to those air pollutants. Treatment groups will include forty healthy young adults who will be given dietary supplementation of fish oil or olive oil. A control group will consist of 20 healthy volunteers who will receive no supplements. After 4 weeks, subjects will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day. Cardiac rhythm, pulmonary function, vascular responses, endothelial function, and markers of coagulation and airway inflammation pre- and post- ozone exposure will be measured. This study is designed to build on the previous nutritional supplement interventional studies (UNC IRB # 07-0190 and UNC IRB # 11-1807), in order to understand the mechanism of action of particulate pollutants in comparison to that of ozone, a known oxidant air contaminant. Participants: A total of sixty healthy 18-35 year-old male and female subjects will be involved in the study. Procedures (methods): Forty healthy young adults will receive dietary supplementation consisting of fish oil or olive oil for 4 weeks. The control group includes 20 healthy volunteers who will receive no supplements in the study. After 4 weeks of supplementation or control regiment, each subject will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day.
Status | Completed |
Enrollment | 44 |
Est. completion date | December 18, 2020 |
Est. primary completion date | December 18, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 35 Years |
Eligibility | Inclusion Criteria: - Age 18-35 years old healthy male and female (19=BMI=30). - Physical conditioning allowing intermittent, moderate exercise for 2 hours, and ability to complete the exposure exercise regimen chosen to induce a minute ventilation rate of 20 L/min/m² for 15 minutes without exceeding 80% of predicted maximal heart rate. - Normal resting electrocardiography (ECG) - Normal lung function - Oxygen saturation greater than 94% at the time of physical exam. - Individuals whose blood omega-3 index is 5% or lower at the time of screening. Exclusion Criteria: 1. Individuals with a history of acute or chronic cardiovascular disease, chronic respiratory disease, cancer (possible exception for history of non-melanoma skin cancer), rheumatologic disease, neuromuscular disease, or immunodeficiency state. 2. Individuals with a cardiovascular disease risk score greater than 10% using the American College of Cardiology and the American Heart Association Atherosclerotic Cardiovascular Disease risk calculator. (Based on the 10-year risk of heart disease or stroke using the Atherosclerotic Cardiovascular Disease algorithm published in 2013 American College of Cardiology/American Heart Association Guideline on the Assessment of Cardiovascular risk.) 3. Uncontrolled hypertension (>150 systolic, >90 diastolic). 4. Individuals who are diabetic (previously diagnosed or with hemoglobin A1c level >6.4%). 5. Individuals with asthma or a history of asthma. 6. Individuals who are allergic to chemical vapors or gases. 7. Individuals who have skin allergy to tape or electrodes. 8. Individuals is pregnant, attempting to become pregnant or breastfeeding. 9. Individuals who are currently smoking (including vaping, hookah and e-cigarette) or have smoking history within 1 year of study (defined as more than 1 pk/yr in the past year) or have a greater than/equal to a 5 pack year smoking history. 10. Individuals living with a smoker who smokes inside the house. 11. Individuals who are regularly exposed to high levels of vapors, dust, gases, or fumes. 12. Individuals that do not understand or speak English. 13. Individuals that are unable to perform the exercise required for the study. 14. Individuals who are taking I^2-blocker medications. 15. Individuals who are allergic to fish or omega-3 fatty acids, or are on prescription of taking omega-3 fish oil as therapy. 16. Individuals that are unwilling or unable to stop taking medications that may impact the results of ozone challenge for the duration of the study. Medications not specifically mentioned here may be reviewed by the investigators prior to an individuals inclusion in the study. 17. Individuals who are unwilling or unable to stop taking any current dietary supplements for the duration of the study. Prebiotics and probiotics are acceptable. 18. Individuals who are unwilling or unable to adhere to study specific dietary restrictions (see details under A.4.2 dietary instruction). 19. Individuals who have unspecified illnesses, which in the judgment of the investigators might increase the risk associated with ozone inhalation will be a basis for exclusion. 20. Individuals with bleeding/clotting disorders. 21. Individuals who are not willing to participate the induced sputum procedure on the training day. Temporary exclusion criteria: 1. Individuals who have recent (within 6 month) abdominal and/or eye surgery, or with any types of hernia, as well as any other contraindications for raised intra-abdominal pressure. 2. Individuals who have had an acute respiratory illness within 4 weeks. 3. Individuals who are currently taking systemic steroids, oral anticoagulants, over-the counter pain medications (such as aspirin, Advil, Aleve) or nonsteroidal anti-inflammatory drugs, or have taken these medications within the last 14 days. 4. Individuals who have active allergies. Use of other medications will be evaluated on a case-by-case basis. There is the potential that an individuals current medication use will preclude them from participating in the study at the current time, but they may be reassessed and potentially rescheduled for participation at a later time. |
Country | Name | City | State |
---|---|---|---|
United States | U.S. Environmental Protection Agency Human Studies Facility | Chapel Hill | North Carolina |
Lead Sponsor | Collaborator |
---|---|
University of North Carolina, Chapel Hill | Environmental Protection Agency (EPA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in forced expired volume in the first second (FEV1) from air exposure (Day 1) to ozone exposure (Day 2) | FEV1 is determined by spirometry | Day 1, Day 2 | |
Secondary | endothelial cell function 1 hour post-exposure | Brachial artery ultrasound will be used to evaluate flow-mediated dilatation which will be performed in the Human Studies Facility (HSF) at U.S. Environmental Protection Agency (EPA) using an ultrasound instrument. The diameter of the brachial artery will be measured at baseline and during reactive hyperemia. | 1 hour pre-exposure, 1 hour post-exposure | |
Secondary | endothelial cell function 18 hour post-exposure | Brachial artery ultrasound will be used to evaluate flow-mediated dilatation which will be performed in the HSF at EPA using an ultrasound instrument. The diameter of the brachial artery will be measured at baseline and during reactive hyperemia. | 1 hour pre-exposure, 18 hour post-exposure | |
Secondary | diameters of retinal arteries and veins 1 hour post-exposure | Retinal images will be taken using an FDA-approved, commercially available, non-mydriatic fundus camera. Images will be taken from both eyes. | 30 min pre-exposure, 1 hour post-exposure | |
Secondary | diameters of retinal arteries and veins 18 hour post-exposure | Retinal images will be taken using an FDA-approved, commercially available, non-mydriatic fundus camera. Images will be taken from both eyes. | 30 min pre-exposure, 18 hour post-exposure | |
Secondary | airway inflammation 4 hour post-exposure | Sputum induction will be performed to determine the airway inflammation. | 6 weeks prior to the exposure, 4 hour post-exposure | |
Secondary | Heart rate variability 1 hour post-exposure | Heart rate variability will be collected by the Holter monitor. | 1 hour pre-exposure, 1 hour post-exposure | |
Secondary | Heart rate variability 18 hour post-exposure | Heart rate variability will be collected by the Holter monitor. | 1 hour pre-exposure, 18 hour post-exposure | |
Secondary | Blood fatty acids 2 hour post-exposure | Blood sample will be collected for fatty acids analysis | 6 weeks prior to the exposure, 2 hours pre-exposure | |
Secondary | Blood fatty acids 30 min post-exposure | Blood sample will be collected for fatty acids analysis | 2 hour pre-exposure, 30 min post-exposure | |
Secondary | Blood fatty acids 18 hour post-exposure | Blood sample will be collected for fatty acids analysis | 2-hour pre-exposure, 18 hour post-exposure | |
Secondary | Blood cholesterol 2 hour post-exposure | Blood sample will be collected for measuring the cholesterol level | 6 weeks prior to the exposure, 2 hours pre-exposure | |
Secondary | Blood cholesterol 30 min post-exposure | Blood sample will be collected for measuring the cholesterol level | 2 hour pre-exposure, 30 min post-exposure | |
Secondary | Blood cholesterol 18 hour post-exposure | Blood sample will be collected for measuring the cholesterol level | 2-hour pre-exposure, 18 hour post-exposure | |
Secondary | Forced expired volume in the first second (FEV1) 18 hour post-exposure | Forced expired volume in the first second (FEV1) is determined by the spirometry | immediate post-exposure to ozone within 30 min, 18 hour post-exposure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |